The Psoriasis and Psoriatic Arthritis Pocket Guide - Treatment Algorithms and Management Options
This is the fourth edition of The Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment Algorithms and Management Options. The previous editions were well-received by dermatologists. Since the publication of the third edition, several new psoriasis treatments have become available, and the medical community has more experience with biological treatments in the management of psoriasis. The National Psoriasis Foundation has revised this publication again to provide more up-to-date guidance for managing patients with moderate to severe psoriasis and to put the role of biologics, no longer new drugs, into perspective.
Abby S. Van Voorhees, M.D.
Chair of Dermatology
Eastern Virginia Medical School
Steven R. Feldman, M.D., Ph.D.
Professor of Dermatology, Pathology & Public Health Sciences
Wake Forest School of Medicine
Mark G. Lebwohl, M.D.
Professor and Chairman, Department of Dermatology
Mount Sinai School of Medicine
New York, N.Y.
Christopher Ritchlin, M.D., MPH
Chief, Department of Medicine, Allergy/Immunology and Rheumatology (SMD)
University of Rochester Medical Center
Arthur Kavanaugh, M.D.
Professor of Clinical Medicine
Director, Center for Innovative Therapy (CIT)
University of California, San Diego School of Medicine
San Diego, Calif.
TREATING PATIENTS IN PRACTICE
Patients should be fully educated about all aspects of their disease, including all potential systemic-related disorders. Each patient should also receive a specific, personalized treatment plan.
After studying this handbook, physicians should be able to:
- Define the severity of psoriasis and develop an appropriate therapy plan.
- Explain the profound emotional, social and physical impact psoriatic disease has on the patient.
- Understand the important comorbidities associate with psoriasis.
- Differentiate psoriasis from other diseases after evaluating patients who present with similar types of skin lesions.
- Diagnose patients who have moderate disease (3 percent to 10 percent body involvement) and severe disease (>10 percent body involvement)